Comparing effects of alpha-blocker management on acute urinary retention secondary to benign prostatic hyperplasia: A systematic review and network meta-analysis

Chute, 1993, The prevalence of prostatism: a population-based survey of urinary symptoms, J Urol, 150, 85, 10.1016/S0022-5347(17)35405-8 Jacobsen, 1997, Natural history of prostatism: risk factors for acute urinary retention, J Urol, 158, 481, 10.1016/S0022-5347(01)64508-7 Emberton, 2008, The Reten-World survey of the management of acute urinary retention: preliminary results, BJU Int, 101, 27, 10.1111/j.1464-410X.2008.07491.x Manikandan, 2004, Management of acute urinary retention secondary to benign prostatic hyperplasia in the UK: a national survey, BJU Int, 93, 84, 10.1111/j.1464-410X.2004.04562.x Caine, 1975, Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck, Br J Urol, 47, 193, 10.1111/j.1464-410X.1975.tb03947.x Altarac, 2006, [Alpha-adrenergic blockers as a support in the treatment of acute urinary retention], Lijec Vjesn, 128, 233 Fisher, 2014, The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men, Cochrane Database Syst Rev Guang-Jun, 2015, Alpha(1)-blockers in the management of acute urinary retention secondary to benign prostatic hyperplasia: a systematic review and meta-analysis, Ir J Med Sci, 184, 23, 10.1007/s11845-014-1094-3 Yoon, 2015, Systematic review and meta-analysis on management of acute urinary retention, Prostate Cancer Prostatic Dis, 18, 297, 10.1038/pcan.2015.15 Choi, 2017, Efficacy and safety of silodosin in the treatment of lower urinary tract symptoms in elderly men taking antihypertensive medications, Prostate Int, 5, 113, 10.1016/j.prnil.2017.02.001 Zeif, 2009, Alpha blockers prior to removal of a catheter for acute urinary retention in adult men, Cochrane Database Syst Rev, 10.1002/14651858.CD006744.pub2 Moher, 2015, Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement, Syst Rev, 4, 1, 10.1186/2046-4053-4-1 Higgins, 2011, The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928 Kara, 2014, Is the double dose alpha-blocker treatment superior than the single dose in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia?, Urol J, 11, 1673 Fulton, 1995, Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia, Drugs, 49, 295, 10.2165/00003495-199549020-00011 Caine, 1976, The use of alpha-adrenergic blockers in benign prostatic obstruction, Br J Urol, 48, 255, 10.1111/j.1464-410X.1976.tb03013.x Alan McNeill, 2004, The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction, Eur Urol, 45, 325, 10.1016/j.eururo.2003.10.001 Lerner, 2021, Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management, J Urol, 206, 806, 10.1097/JU.0000000000002183 Professionals, 2021, 13 Karavitakis, 2019, Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis, Eur Urol, 75, 788, 10.1016/j.eururo.2019.01.046 Oelke, 2013, EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction, Eur Urol, 64, 118, 10.1016/j.eururo.2013.03.004 Hagiwara, 2016, Efficacy and safety of silodosin and dutasteride combination therapy in acute urinary retention due to benign prostatic hyperplasia: a single-arm prospective study, Biomed Res Int, 2016, 4975851, 10.1155/2016/4975851 Baboudjian, 2022, Best nonsurgical managements of acute urinary retention: what’s new?, Curr Opin Urol, 32, 124, 10.1097/MOU.0000000000000969 Bansal, 2017, Predictors of successful trial without catheter following acute urinary retention in benign prostatic enlargement: A single centre, multivariate analysis, Neurourol Urodyn, 36, 1757, 10.1002/nau.23194 Tammela, 1986, Postoperative urinary retention. I. Incidence and predisposing factors, Scand J Urol Nephrol, 20, 197, 10.3109/00365598609024494 Lee, 2007, Analysis of risk factors for acute urinary retention after non-urogenital surgery, Korean Journal of Urology, 48, 1277, 10.4111/kju.2007.48.12.1277 Lau, 2004, Management of postoperative urinary retention: a randomized trial of in-out versus overnight catheterization, ANZ J Surg, 74, 658, 10.1111/j.1445-1433.2004.03116.x Wein, 2007, 2011 Bhomi, 2011, Factors predicting the success of a trial without catheter in acute urinary retention secondary to benign prostatic hyperplasia, Nepal Med Coll J, 13, 178 Djavan, 1997, Urodynamic assessment of patients with acute urinary retention: is treatment failure after prostatectomy predictable?, J Urol, 158, 1829, 10.1016/S0022-5347(01)64139-9 Kumar, 2000, A prospective study of conservatively managed acute urinary retention: prostate size matters, BJU Int, 86, 816, 10.1046/j.1464-410x.2000.00918.x Zeif, 2010, Predictors of successful trial without catheter in acute urinary retention, British Journal of Medical and Surgical Urology, 3, 5, 10.1016/j.bjmsu.2009.09.028 Chia, 2003, Correlation of intravesical prostatic protrusion with bladder outlet obstruction, BJU Int, 91, 371, 10.1046/j.1464-410X.2003.04088.x Tan, 2003, Intravesical prostatic protrusion predicts the outcome of a trial without catheter following acute urine retention, J Urol, 170, 2339, 10.1097/01.ju.0000095474.86981.00 Mariappan, 2007, Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study, J Urol, 178, 573, 10.1016/j.juro.2007.03.116 Madersbacher, 2012, What are the causes and consequences of bladder overdistension?: ICI-RS 2011, Neurourol Urodyn, 31, 317, 10.1002/nau.22224 Keten, 2015, Determination of the efficiency of 8 mg doxazosin XL treatment in patients with an inadequate response to 4 mg doxazosin XL treatment for benign prostatic hyperplasia, Urology, 85, 189, 10.1016/j.urology.2014.10.004 McNeill, 2005, Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study, Urology, 65, 83, 10.1016/j.urology.2004.07.042 Tiong, 2009, Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia, Urol Int, 83, 44, 10.1159/000224867 Patil, 2017, Comparison of tamsulosin and silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia in patients planned for trial without catheter. A prospective randomized study, Central European Journal of Urology, 70, 259 Parikh, 2020, Comparison of the effects of tamsulosin, silodosin, and alfuzosin on catheter-free trials after acute urinary retention due to benign prostatic hyperplasia: A prospective study, Urological Science, 31, 188, 10.4103/UROS.UROS_11_20 Agrawal, 2009, A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia, Indian Journal of Urology, 25, 474, 10.4103/0970-1591.57917 Maldonado-Ávila, 2014, A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth, Int Urol Nephrol, 46, 687, 10.1007/s11255-013-0515-y Prieto, 2008, Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia, Urol Int, 81, 66, 10.1159/000137643 Kumar, 2013, Prospective randomized placebo-controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention, Urology, 82, 171, 10.1016/j.urology.2013.02.020 McNeill, 1999, Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled, BJU Int, 84, 622, 10.1046/j.1464-410x.1999.00277.x Lucas, 2005, Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia, BJU Int, 95, 354, 10.1111/j.1464-410X.2005.05299.x Al-Hashimi, 2007, Alfuzosin 10 mg once daily in the management of acute urinary retention of benign prostatic hyperplasia: a double-blind, placebo-controlled study, Current Urology, 1, 28, 10.1159/000106525 Shah, 2002, Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention, Eur Urol, 42, 329, 10.1016/S0302-2838(02)00319-6